compani lly-
invest summari reiter overweight rate rais
pt share increas pt driven multipl
expans think deserv continu sale growth margin
expans pipelin advanc still underappreci opinion
 valuat use blend ev/ebitda multipl increas
peer averag dcf analysi ev/ebit exit multipl
increas peer averag ev/ebit arriv
new pt think deserv trade premium multipl
peer stronger growth prospect also includ
revenu new product opportun emgal model yet
would lower valuat multipl
 chang mind report better expect data
combin product easd think could overtak
inject potenti oral market pleas see recent note
detail compani also recent receiv approv emgal along
potenti approv tanezumab lasmitidan give
foothold pain could new blockbust vertic compani
disclosur section may found page
use blend ev/ebitda multipl increas peer averag
dcf analysi ev/ebit exit multipl increas peer
averag ev/ebit arriv pt
greater expect brand and/or gener competit lilli key drugs/product
number lilli top-sel human pharmaceut product recent lost
lose next sever year signific patent protect and/or data protect
well key countri outsid certain signific product longer
effect exclus patent protect data protect non-biolog product
loss exclus whether expir consequ litig typic result
entri one gener competitor lead rapid sever declin
revenu especi histor outsid market penetr gener
follow loss exclus rapid pervas howev gener
market penetr increas mani market outsid includ japan europ
mani countri emerg market biolog humalog humulin erbitux
cyramza trulic taltz loss exclus may may result near-term entri
competitor version biosimilar due develop timelin manufactur challeng
and/or uncertainti regulatori pathway approv competitor version
setback lilli pipelin could headwind compani futur growth prospect
lilli compet larg number multi-national pharmaceut compani biotechnolog
compani gener pharmaceut compani compet success lilli must
continu deliv market innov cost-effect product meet import medic
lilli human pharmaceut busi subject increas govern price control
public privat restrict price reimburs access drug
could materi advers effect busi public privat payer take
increasingli aggress step control expenditur human pharmaceut
place restrict price reimburs patient access lilli medic
pressur could neg affect futur revenu net incom lilli expect
price reimburs access pressur govern privat payer insid
outsid becom sever
manufactur difficulti disrupt could lead product suppli problem
anim health manufactur complex highli regul
manufactur difficulti lilli facil contract facil failur refus
contract manufactur suppli contract quantiti could result product shortag
lead lost revenu difficulti disrupt could result qualiti regulatori
complianc problem natur disast mechan inform technolog system failur
inabl obtain sole-sourc raw intermedi materi addit given difficulti
predict sale new product long lead time necessari expans
regulatori qualif pharmaceut manufactur capac possibl lilli
could difficulti meet unanticip demand new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
exhibit catalyst event calendar
exhibit catalyst event calendar continu
eli mm except per share amount margin revenu sell rate per share expenditur outlooksal compound-annual-growth-rate oper margin cantor fitzgerald research compani reportsnot financi guidanc tabl guidanc gross margin revenu report guidanc tax rate report guidanc ep report updat guidanc impli non-gaap ep assum price increas remaind lower ep due expect gener competit ciali septemb higher second half expens support addit late stage invest includ taltz acquisit launch invest galcanezumab lesser extent higher revenu realiz compani complet previously-announc billion share repurchas program author new billion share repurchas increas prior guidanc due strong perform across pharmaceut portfolio particularli diabet well higher collabor revenu partial off-set impact foreign exchang rate revenu growth still expect driven new product includ trulic taltz basaglar jardianc verzenio cyramza olumi expect minimum averag annual revenu growth constant currenc expect exclus fx intern inventori sold minimum oper margin revenu expect lever time function tax reform base capit alloc prioriti cash flow exhibit incom statement analysi
million compound-annual-growth-rate year end decemb oper expens oper net dilut changetot oper expens incom nmnmnmnmnmnmnmnmnmnmnmoper net dilut cantor fitzgerald research compani report exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat agreement astrazeneca co-develop charg relat impact venezuelan financi crisi includ signific deterior bolivar integr sever cost relat acquisit novarti anim health global sever cost asset impair relat closur anim health manufactur facil ireland exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat busi develop activ primarili driven acquisit colucid pharmaceut inventori step-up cost associ acquisit boehring ingelheim vetmedica felin canin rabi vaccin portfolio charg primarili associ effort reduc compani cost structur includ voluntari earli retir program charg relat recent enact tax reform legisl includ one-tim repatri transit tax also known toll tax exclud amort intang primarili associ cost market product acquir licens third parti charg primarili associ asset impair restructur charg relat decis end posilac rbst product augusta georgia manufactur site well expens associ review strateg altern busi begin pension postretir benefit cost compon servic cost present incom expens exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat busi develop activ primarili driven acquisit armo bioscienc aurka pharma well collabor sigilon therapeut charg primarili associ asset impair restructur charg relat suspens commerci activ imrestor well expens associ review strateg altern busi exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb product intern pipelin product anim health changeu product intern anim health cantor fitzgerald research compani report cardio includ zalutia livalo reopro endocrinolog includ axiron evista acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ vancocin ceclor keflex licens fee incom biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version exhibit annual sale analysi
 product intern pipelin product anim health cantor fitzgerald research compani report cardio includ zalutia livalo reopro endocrinolog includ axiron evista acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ vancocin ceclor keflex licens fee incom biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version year end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas net proce sale acquisit net cash acquired- net cash use invest flow financ activ repay issuanc long term dividend net cash use provid financ effect exchange-r cash net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt current total current plant properti identifi total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling total liabil stockhold sourc cantor fitzgerald research compani report octob
 co engag discoveri develop manufactur sale pharmaceut product oper two segment
product anim health product segment includ discoveri develop
manufactur market sale human pharmaceut product world-wide follow therapeut area neurosci
endocrinolog oncolog cardiovascular anim health segment oper divis
develop manufactur market product food companion anim anim health product includ rumensin tylan
posilac paylean product livestock poultri well trifexi comforti product companion anim
